Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amur Minerals ( (GB:CRTX) ) has shared an update.
CRISM Therapeutics Corporation has announced the establishment of a Scientific Advisory Board (SAB) to guide its upcoming clinical trial application for ChemoSeed in glioblastoma. The SAB, comprising experts in neuro-oncology, will provide valuable insights for the company’s Phase II clinical trial, potentially strengthening CRISM’s position in the oncology drug delivery market.
More about Amur Minerals
CRISM Therapeutics Corporation is a UK-based innovative drug delivery company focused on enhancing the clinical performance of cancer treatments for solid tumors through localized chemotherapy drug delivery. Its lead product, ChemoSeed, is designed to be implanted directly into tumors or resection margins, particularly in glioblastoma cases, to bypass the blood-brain barrier and ensure effective treatment.
Average Trading Volume: 63,207
Technical Sentiment Signal: Strong Buy
Current Market Cap: £1.61M
See more insights into CRTX stock on TipRanks’ Stock Analysis page.